APA (7th ed.) Citation

CE, C., M, O., SC, L., R, S., V, H., WP, Y., . . . BC, G. (2023). A Phase I, First-in-Human Study of PRL3-zumab in Advanced, Refractory Solid Tumors and Hematological Malignancies. Targeted oncology, 18(3), 391. https://doi.org/10.1007/s11523-023-00962-w

Chicago Style (17th ed.) Citation

CE, Chee, et al. "A Phase I, First-in-Human Study of PRL3-zumab in Advanced, Refractory Solid Tumors and Hematological Malignancies." Targeted Oncology 18, no. 3 (2023): 391. https://doi.org/10.1007/s11523-023-00962-w.

MLA (9th ed.) Citation

CE, Chee, et al. "A Phase I, First-in-Human Study of PRL3-zumab in Advanced, Refractory Solid Tumors and Hematological Malignancies." Targeted Oncology, vol. 18, no. 3, 2023, p. 391, https://doi.org/10.1007/s11523-023-00962-w.